The Binaytara Foundation is facilitating three conferences with varying focuses at the beginning of the year. These meetings include BTF’s ASH Annual Meeting Review in Portland, OR on January 6-7; Highlights from SABCS on January 21 in Seattle, WA; and the Multidisciplinary Thoracic Oncology Symposium on February 3-4 in San Diego, CA.
At this meeting, faculty will present important information, findings, and impacts on care from the ASH 22 conference. Attendees will have the opportunity to hear from hematology experts and participate in discussions relevant to their work and patients.
Dr. Sri Tantravahi is the conference chair and will be joined by faculty from the Mayo Clinic, University of Washington, Fred Hutch, and Oregon Health & Science University, among others. The meeting will feature a tumor board-style case-based discussion moderated by Dr. Tantravahi and Dr. Aaron Goodman. Dr. Natasha Goodwin of Providence Healthcare, Dr. Eva Medvedova of Oregon Health & Science University, and Dr. Curtis Lachowiez of Oregon Health & Science University will be panelists.
Dr. Fengting Yan and Dr. Janice Kim are leading this conference as the co-chairs and hope to offer key advances, presentations, and impacts from the SABCS meeting in Texas. Some doctors may have been unable to attend, and Dr. Yan wants to provide access to the information and continue the conversation.
“We are bringing all the local experts together to focus on the most relevant updates for the audience and making it interactive with case discussions.”Dr. Fengting Yan
Highlights from SABCS will feature leading oncologists in the field of breast cancer from around the country, including Dr. Nancy Davidson, Dr. Angelena Crown, and Dr. Wendy Wang. These physicians represent various specialties and expertise within breast oncology.
Hosted in beautiful San Diego, this conference will focus on thoracic malignancies and the current management strategies for lung cancer. Drs. Kristin Higgins and Sandip Patel have gathered leading thoracic oncologists who will share their expertise. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted therapies for thoracic oncology.
Doctors from a wide range of institutions and universities are among those speaking, including City of Hope, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Rutgers University Health, and Scripps Health.
The Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal. Donate here to change lives!
2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty faculty highlight FDA approved Featured head & neck cancer surgery in Nepal healthcare equity hematological malignancies Journal leukemia Lung cancer lymphoma multiple myeloma Nepal Nepal cancer care oncology oncology CME Opinion peer-reviewed journal SCHD upcoming conferences video news Volunteer
By Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renalMore
On March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patientsMore
On February 9th, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly for adult patients with recurrent or advanced endometrial cancer (EC)More
Dr. Daneng Li of City of Hope Comprehensive Cancer Center shares a recent abstract from ASCO GI, NRG/RTOG 1112, a randomized phaseMore
On January 27, 2023, the U.S. Food and Drug Administration approved elacestrant for postmenopausal, non-pregnant women and adult men with advanced orMore